KaloCyte, Inc.

12:30 PM - 12:45 PM, Tuesday, June 4, 2019 ・ SuS - Hall E, Booth 3971, Level 200
Biotechnology company that has developed a bio-inspired artificial red blood cell to treat blood loss when donor or stored erythrocytes are unavailable, undesirable, or in short supply, such as in mass casualty events, patients at risk for immune system rejection, high-stress military settings, or developing countries with lacking medical resources. The technology uses nano-encapsulated human hemoglobin that mimics native erythrocyte physiology and a synthetic nanoparticle structure that eliminates the need for blood typing and allows for benign interactions with vasculature. This company has received funding from the NIH and the DoD to support the development of the artificial red blood cell technology and will advance to first-in-human trials.
President & CEO
KaloCyte, Inc.